CN1788018B - 铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体 - Google Patents

铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体 Download PDF

Info

Publication number
CN1788018B
CN1788018B CN200480013138XA CN200480013138A CN1788018B CN 1788018 B CN1788018 B CN 1788018B CN 200480013138X A CN200480013138X A CN 200480013138XA CN 200480013138 A CN200480013138 A CN 200480013138A CN 1788018 B CN1788018 B CN 1788018B
Authority
CN
China
Prior art keywords
human monoclonal
monoclonal antibodies
antibody
nucleic acid
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200480013138XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1788018A (zh
Inventor
A·B·朗
M·P·霍恩
M·A·英博登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kenta Biotech AG
Original Assignee
Kenta Biotech AG
Berna Biotech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kenta Biotech AG, Berna Biotech AG filed Critical Kenta Biotech AG
Publication of CN1788018A publication Critical patent/CN1788018A/zh
Application granted granted Critical
Publication of CN1788018B publication Critical patent/CN1788018B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200480013138XA 2003-05-14 2004-04-28 铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体 Expired - Fee Related CN1788018B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03010836.9 2003-05-14
EP03010836A EP1479695B1 (de) 2003-05-14 2003-05-14 Humaner monoklonaler Antikörper spezifisch für Lipopolysacchariden (LPS) des Serotyps IATS O6 von Pseudomonas aeruginosa
PCT/EP2004/004485 WO2004101622A1 (en) 2003-05-14 2004-04-28 Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats 06 of pseudomonas aeruginosa

Publications (2)

Publication Number Publication Date
CN1788018A CN1788018A (zh) 2006-06-14
CN1788018B true CN1788018B (zh) 2012-04-25

Family

ID=33040937

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200480013138XA Expired - Fee Related CN1788018B (zh) 2003-05-14 2004-04-28 铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体

Country Status (9)

Country Link
US (1) US7597893B2 (de)
EP (1) EP1479695B1 (de)
KR (1) KR100910097B1 (de)
CN (1) CN1788018B (de)
AT (1) ATE458006T1 (de)
CA (1) CA2525657C (de)
DE (1) DE60331292D1 (de)
ES (1) ES2338105T3 (de)
WO (1) WO2004101622A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010005871A (es) * 2007-11-30 2010-06-09 Kalobios Pharmaceuticals Inc Anticuerpos al antigeno de pcrv de pseudomonas aeruginosa.
BRPI1013427A2 (pt) * 2009-04-09 2016-04-05 Kenta Biotech Ag anticorpo monoclonal humano para lipopolissacarídeos (lps) de serotipo iats o1 de pseudomonas aeruginosa, hibridoma, ácido nucleico, vetor, celula hospedeira, metodo para produzir o anticorpo monoclonal humano, composição farmaceutica, uso de um anticorpo monoclonal humano, kit de teste para diagnostico de p. aeruginosa em uma amostra
ITFI20090230A1 (it) * 2009-11-04 2011-05-05 Azienda Ospedaliero Universitaria C Areggi Glicoconiugato sintetico immunogeno utile per l'immunoterapia del melanoma.
WO2011102551A1 (en) * 2010-02-18 2011-08-25 Meiji Seika Kaisha, Ltd. Antibody against serotype e lipopolysaccharide of pseudomonas aeruginosa
EP2361989A1 (de) * 2010-02-26 2011-08-31 Kenta Biotech AG Verfahren und Kits zur Serotypisierung von Pseudomonas aeruginosa und Oligonukleotidsequenzen zur Verwendung in solchen Methoden und Kits
SG10201913690SA (en) 2011-02-08 2020-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2015002954A1 (en) * 2013-07-03 2015-01-08 Synglyco Pharmaceuticals, Inc. Synthetic oligosaccharides for p. aeruginosa vaccine
KR20180101341A (ko) 2015-11-10 2018-09-12 비스테라, 인크. 리포폴리사카라이드에 특이적으로 결합하는 항체 분자-약물 접합체 및 그의 용도
CN105424929B (zh) * 2015-11-24 2017-08-08 四川夹金山逢春养殖科技有限公司 一种铜绿假单胞菌抗体检测试剂盒及检测方法
CA3049449A1 (en) 2017-01-18 2018-07-26 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
KR20210035846A (ko) 2018-07-24 2021-04-01 메디뮨 엘엘씨 에스. 아우레우스 클럼핑 인자 A(ClFA)에 지향되는 항체
CA3115633A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Combinations of anti-staphylococcus aureus antibodies
AU2021248643A1 (en) 2020-04-03 2022-10-27 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04211393A (ja) * 1990-02-08 1992-08-03 Sumitomo Pharmaceut Co Ltd ヒトモノクローナル抗体及びそれを有効成分とする緑膿菌感染症治療剤
AU8886601A (en) * 2000-09-07 2002-03-22 John R Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
NZ530765A (en) * 2001-06-26 2006-11-30 Amgen Fremont Inc Antibodies that bind OPGL and compositions and methods for the treatment of bone diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S.HEMACHANDRA ET AL..Human monoclonal antibodies against pseudomonasaeruginosa lipopolysaccharide derived from transgenicimmunoglobulin loci are opsonic and protective against fatalpesudomonas sepsis.INFECTION AND IMMUNITY69 4.2001,69(4),全文. *

Also Published As

Publication number Publication date
DE60331292D1 (de) 2010-04-01
CN1788018A (zh) 2006-06-14
KR20060006967A (ko) 2006-01-20
KR100910097B1 (ko) 2009-07-30
EP1479695A1 (de) 2004-11-24
CA2525657C (en) 2011-11-29
CA2525657A1 (en) 2004-11-25
ATE458006T1 (de) 2010-03-15
US7597893B2 (en) 2009-10-06
ES2338105T3 (es) 2010-05-04
US20060093610A1 (en) 2006-05-04
WO2004101622A1 (en) 2004-11-25
EP1479695B1 (de) 2010-02-17

Similar Documents

Publication Publication Date Title
JP3421970B2 (ja) ペプチド免疫原
RU2529946C9 (ru) Моноклональное антитело человека против альфа-токсина из s. aureus и его применение в лечении или предотвращении образования абсцесса
CN1788018B (zh) 铜绿假单胞菌血清型iats o6的脂多糖(lps)特异性的人单克隆抗体
CA2434762A1 (en) Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
DE69010001T2 (de) Synthetisches pseudomonas aeruginosa pilin-peptid und verwandte impfstoffe und diagnostika.
IL184774A (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats 011 serotype
JP5124062B2 (ja) フィブロネクチン結合タンパク質組成物および使用法
US20120114657A1 (en) Human Monoclonal Antibody Specific for Lipopolysaccharides (LPS) of Serotype IATS 01 of Pseudomonas Aeruginosa
JP2005514053A6 (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
JP2005514053A (ja) グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体
JP2639422B2 (ja) シュードモナスアエルギノーザ鞭毛に対するモノクローナル抗体
CN1330375C (zh) 识别维罗毒素ⅱ的人源化抗体和产生它的细胞系
EP0450573A2 (de) Antikörper für die Behandlung und die Diagnose von Pseudomonas aeruginosa Infektionen
KR100506118B1 (ko) 수막염균증 백신 조성물
JPH0411897A (ja) 抗緑膿菌外毒素ａヒトモノクローナル抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: KENTA BIOISYSTECH CO., LTD.

Free format text: FORMER OWNER: BERNA BIOTECH AG

Effective date: 20060728

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20060728

Address after: Bern

Applicant after: Kenta Biotech AG

Address before: Bern

Applicant before: Berna Biotech AG

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20060614

CI01 Publication of corrected invention patent application

Correction item: Rejection of patent application

Correct: Dismiss

False: Reject

Number: 32

Volume: 26

ERR Gazette correction

Free format text: CORRECT: PATENT APPLICATION REJECTION AFTER THE ANNOUNCEMENT; FROM: REJECTION TO: CANCEL REJECTION

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120425

Termination date: 20130428